A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma
- PDF / 3,026,249 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 156 Views
RESEARCH ARTICLE
Open Access
A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma Hanliang Jiang*, Shan Xu and Chunhua Chen
Abstract Background: Lung adenocarcinoma (LUAD) is a major cause of cancer death. Therefore, identifying potential prognostic risk factors is critical to improve the survival of patients with LUAD. Methods: Here, relevant datasets were downloaded from TCGA and GEO databases to screen the differentially expressed genes (DEGs). Univariate Cox analysis, LASSO regression analysis and multivariate Cox analysis were conducted on the DEGs combined with TCGA clinical data, and finally a risk assessment model based on 10 feature genes was constructed. Results: The prognosis of patients was evaluated after the patients were grouped based on the median risk score and the results showed that the survival time of patients in the high-risk group was significantly shorter than that in the low-risk group. ROC analysis showed that the AUC values of the 1, 3, 5-year survival were 0.753, 0.724, and 0.73, respectively, indicating that the model was precise in predicting the prognosis, which was also verified in the external dataset GSE72094. In addition, a significant correlation was found between the risk score and the clinical stages of LUAD, that is, a later stage always corresponded to a higher risk score. Then, we performed survival analysis on the 10 feature genes independently in the TCGA-LUAD dataset through the GEPIA database, finding that the high expression of 6 genes (COL5A2, PLEK2, BAIAP2L2, S100P, ZIC2, SFXN1) was associated with the poor prognosis of LUAD patients. Conclusion: To sum, this study established a 10-gene risk assessment model and further evaluated its value in predicting LUAD prognosis, which provided a new method for the prognosis prediction of LUAD. Keywords: LUAD, Feature gene, Risk assessment model, Prognosis prediction
Background Lung cancer had become the most frequently diagnosed cancers worldwide, according to the latest cancer statistics released in 2018 [1]. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are two subtypes of lung cancer. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the two main types * Correspondence: [email protected] Department of Pulmonary and Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Eastern Qingchun Road, Hangzhou 310016, China
of NSCLC [2], while LUAD accounts for a higher proportion [3]. With the development of molecular targeted therapy and immunotherapy, the survival rate of LUAD has been gradually improved. For example, tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been considered as the standard first-line treatment of advanced LUAD in patients with sensitive EGFR gene mutations [4]. ROS proto-oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) gene are common oncogenes in the targeted therapy of LUAD [5]. In addition, approved immunotherapy for lung cancer i
Data Loading...
